July 25, 2024 03:15 PM EDT

EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events

Max Bayer

Pharma Reporter

European regulators are poised to approve Novo Nordisk’s blockbuster drug Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

EU pan­el fol­lows FDA’s lead on We­govy, rec­om­mend­ing use to pre­vent car­diac events

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events